Edgewise

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

This is a 2-part, open-label study in approximately 9 adults with oHCM. Part A of the study consists of 3 cohorts of approximately 3 participants each administered a single dose of EDG-7500. Part B of the study is an optional multiple-dose treatment period in which approximately 9 participants will receive EDG-7500 once daily for up to 28 days (see Figure 1).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Oct 2024. Study ID: 854859

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).